6533b7d3fe1ef96bd125fea2

RESEARCH PRODUCT

Liquid Biopsy in Gastrointestinal Stromal Tumor

Antonio RussoNadia BarracoAlex Le CesneDaniele FanaleGiuseppe BadalamentiMarta CastigliaLorena Incorvaia

subject

0301 basic medicinemedicine.medical_specialtyStromal cellbusiness.industryGeneral surgeryImatinibTherapeutic decision makingmedicine.diseasedigestive system diseases03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisCancer researchMedicineNeoplasmGastrointestinal stromal tumors (GISTs)Liquid biopsyStromal tumorbusinessneoplasmsTyrosine kinasemedicine.drug

description

Over the past 15 years, gastrointestinal stromal tumors (GISTs) have emerged from a poorly understood neoplasm to a well-defined tumor entity. Starting from 2000, the discovery of gain-of-function mutations involving KIT or PDGFRα (platelet-derived growth factor-α) genes and the development of tyrosine kinase inhibitors (TKIs), such as imatinib, revolutionized dramatically the management of GISTs. Due to the almost continual emergence of new data about biological complexity of GISTs and more sophisticated whole-genome technologies, to date, the role of molecular biology is clinically important to drive therapeutic decision making.

yearjournalcountryeditionlanguage
2017-01-01
https://doi.org/10.1007/978-3-319-55661-1_16